Madrigal Press Releases

Madrigal Pharmaceuticals

Skip to content

About Us
Our Approach
News Room
Investors

News Room

Headlines
Presentations
NASH Experts Webcasts
Media Contact

Headlines

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
November 23, 2021

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
November 12, 2021

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
November 4, 2021

Press Release History

©2020 Madrigal Pharmaceuticals, Inc. All rights reserved.

- About Us
- Our Approach
- News Room
- Investors
- Contact Us
- Legal
- Privacy
- Cookies

Madrigal Pharmaceuticals
200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428

Madrigal Clinical Trials

Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)

Website Developed by Alan Leff Associates, Inc.